MYC and astrocytoma (excluding glioblastoma): The molecular heterogeneity underlying IDH1/2-mutant astrocytoma manifested in feature assessment, with several features such as MYC amplification and MET alterations significant on univariate analysis but not after multiple comparisons correction, similar to that reported as part of cIMPACT-NOW.18,24 We also demonstrate that heterozygous loss of CKDN2A/B conferred a negative impact on overall survival similar to homozygous loss of CDKN2A/B, suggesting prognostic value of CDKN2A/B in glioblastoma even with incomplete loss.